{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+%28Lucentis%29",
    "query": {
      "intervention": "Ranibizumab (Lucentis)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 262,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+%28Lucentis%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T16:26:29.082Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00841373",
      "title": "Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinal Ischemia"
      ],
      "interventions": [
        {
          "name": "Panretinal Photocoagulation",
          "type": "PROCEDURE"
        },
        {
          "name": "Panretinal Photocoagulation and intravitreal injection of ranibizumab",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Southern New England Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2007-07",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00841373"
    },
    {
      "nct_id": "NCT00769145",
      "title": "Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-10",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00769145"
    },
    {
      "nct_id": "NCT00407381",
      "title": "The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Laser photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2006-12",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-31",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407381"
    },
    {
      "nct_id": "NCT05151731",
      "title": "A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Vamikibart",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Sham Procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 394,
      "start_date": "2021-12-31",
      "completion_date": "2025-04-21",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 36,
      "location_summary": "Arcadia, California • Poway, California • Sacramento, California + 33 more",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05151731"
    },
    {
      "nct_id": "NCT03203447",
      "title": "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "suprachoroidal CLS-TA",
          "type": "DRUG"
        },
        {
          "name": "suprachoroidal sham",
          "type": "DRUG"
        },
        {
          "name": "Lucentis or Avastin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearside Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2018-03-05",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 72,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03203447"
    },
    {
      "nct_id": "NCT01644513",
      "title": "Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sequenom, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2012-07",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-12",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01644513"
    },
    {
      "nct_id": "NCT00407355",
      "title": "Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Intravitreal injection of ranibizumab .3 dose",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal injection of Ranibizumab .5 dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peter A Campochiaro, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-01",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407355"
    },
    {
      "nct_id": "NCT03423823",
      "title": "Ziv-aflibercept Efficacy in Better Regulating AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Macular Degeneration",
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ziv-Aflibercept 25 MG/ML [Zaltrap]",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kapil Kapoor",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "50 Years to 99 Years"
      },
      "enrollment_count": 62,
      "start_date": "2017-07-07",
      "completion_date": "2020-06-26",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Virginia Beach, Virginia",
      "locations": [
        {
          "city": "Virginia Beach",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423823"
    },
    {
      "nct_id": "NCT02291887",
      "title": "Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Associated Retinal Consultants, Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2014-12-22",
      "completion_date": "2015-07-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02291887"
    },
    {
      "nct_id": "NCT01492400",
      "title": "Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "dexamethasone Intravitreal Implant",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 363,
      "start_date": "2012-03-09",
      "completion_date": "2014-02-13",
      "has_results": true,
      "last_update_posted_date": "2019-04-17",
      "last_synced_at": "2026-09-29T16:26:29.082Z",
      "location_count": 1,
      "location_summary": "Arlington, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492400"
    }
  ]
}